Ani Pharmaceuticals (ANIP) Other Operating Expenses (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 16 years of Other Operating Expenses data on file, last reported at $114.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $114.3 million; the trailing twelve-month figure through Mar 2026 stood at $113.9 million (changed N/A YoY), and the FY2025 full-year result was -$382000.0, down 107.14% from the prior year.
• Other Operating Expenses advanced to $114.3 million in Q1 2026, from -$87000.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $114.3 million in Q1 2026 to a low of -$295000.0 in Q3 2025.
• A 4-year average of $36.2 million and a median of $26.7 million in 2022 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 672.32% in 2022, while the deepest fall reached 60.35% in 2022.
• Tracing ANIP's Other Operating Expenses over 4 years: stood at $48.1 million in 2022, then sank by 88.88% to $5.3 million in 2024, then sank by 101.63% to -$87000.0 in 2025, then surged by 131501.15% to $114.3 million in 2026.
• Business Quant data shows ANIP's Other Operating Expenses at $114.3 million in Q1 2026, -$87000.0 in Q4 2025, and -$295000.0 in Q3 2025.